CAR-T in Earlier Lines of MM Treatment: Patient Eligibility - Considerations between Ide-cel vs. Cilta-cel

Opinion
Video

Panelists discuss how patient selection criteria and individual characteristics help determine whether ide-cel or cilta-cel is the more appropriate chimeric antigen receptor T-cell therapy choice for early-line treatment in patients with multiple myeloma.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • Which patients do you think about for chimeric antigen receptor T-cell therapy (CAR T) in second-line treatment for relapsed/refractory multiple myeloma (cilta-cel vs ide-cel)?
      • Dr Usmani to ask Dr Mailankody: Can you describe the specific criteria/institutional guidelines used to determine patient eligibility for CAR T referral?
      • How do nonmedical factors (location, money, etc) impact patient selection?
      Related Content